CMV antibody responses in the 4 patients with primary HIV-1 and CMV coinfection
| . | IgG-ELFA (4-6 IU/mL)* . | IgM-EIA index (0.9-01.1)† . |
|---|---|---|
| Patient 1 | ||
| Baseline | < 4 | 2.4 |
| Day 15 | 27 | 4.9 |
| Patient 2 | ||
| Baseline | 6 | 3.3 |
| Day 70 | 73 | 1.4 |
| Patient 3 | ||
| Baseline | < 4 | 0.8 |
| Day 18 | 25 | 10 |
| Patient 4 | ||
| Baseline | < 4 | 2.2 |
| Day 8 | 8 | 5.8 |
| . | IgG-ELFA (4-6 IU/mL)* . | IgM-EIA index (0.9-01.1)† . |
|---|---|---|
| Patient 1 | ||
| Baseline | < 4 | 2.4 |
| Day 15 | 27 | 4.9 |
| Patient 2 | ||
| Baseline | 6 | 3.3 |
| Day 70 | 73 | 1.4 |
| Patient 3 | ||
| Baseline | < 4 | 0.8 |
| Day 18 | 25 | 10 |
| Patient 4 | ||
| Baseline | < 4 | 2.2 |
| Day 8 | 8 | 5.8 |
In patients 1, 3, and 4, the absence of CMV IgG antibodies and the presence of IgM antibodies (borderline positive in patient 3) at baseline, together with the seroconversion at later time points, are unequivocal evidence of primary CMV infection. In patient 2, the borderline level and low avidity (19%) of IgG and the presence of IgM at baseline also suggest a primary CMV infection. The substantial increase in both IgG levels and avidity (60%) at day 70 further supports the diagnosis of primary CMV infection. IU indicates international units.
Determination of the IgG CMV antibodies was performed by an enzyme-linked fluorescent assay (ELFA). Range indicates positive borderline values.
Determination of the IgM CMV antibodies was performed by an enzyme immunoassay (EIA). Range indicates positive borderline values.